OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2024
(1)
2023
(1)
2021
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Not available
S-EPMC8653024
|
biostudies-literature
Cite
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
Not available
S-EPMC10324268
|
biostudies-literature
Cite
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Not available
S-EPMC11873788
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
